Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Mar;4(2):122–126. doi: 10.1128/cdli.4.2.122-126.1997

Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women.

R P Viscidi 1, K L Kotloff 1, B Clayman 1, K Russ 1, S Shapiro 1, K V Shah 1
PMCID: PMC170489  PMID: 9067643

Abstract

A human papillomavirus type 16 (HPV-16) virus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA) was used to measure serum antibody to capsid proteins in 376 sexually active college women who were also screened for the presence of genital HPVs by PCR and interviewed for demographic and behavioral risk factors for HPV infection. The seroprevalence was 46% in women with HPV-16 DNA in the genital tract. The corresponding values for women who harbored other HPV types or no HPV in the genital tract were 30 and 19%, respectively (HPV-16 group versus no-HPV group; odds ratio [OR], 3.7; 95% confidence interval [CI], 1.5 to 8.9). The antibody response was significantly higher among women with a high viral load than among those with a low viral load (median optical density value, 0.838 versus 0.137, P = 0.009). Comparable levels of seroreactivity were observed among women infected with HPV types distantly or closely related genetically to HPV-16. Seroreactivity was significantly associated with an age of 25 to 30 years (OR, 2.3; 95% CI, 1.2 to 4.4), three or more lifetime sexual partners (OR, 2.9; 95% CI, 1.1 to 10), and history of a sexually transmitted disease other than HPV (OR, 3.1; 95% CI, 1.5 to 6.3). The percent seropositivity increased linearly with number of lifetime sexual partners until reaching a plateau at 35% for women with more than six partners (chi for linear trend, P < 0.001). The low sensitivity of HPV-16 VLP-based ELISA may limit the usefulness of the assay as a diagnostic test for HPV-16 infection. However, the assay appears to have adequate specificity and should be useful as an epidemiological marker of HPV-16 infection and sexual behavior.

Full Text

The Full Text of this article is available as a PDF (95.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burkett B. J., Peterson C. M., Birch L. M., Brennan C., Nuckols M. L., Ward B. E., Crum C. P. The relationship between contraceptives, sexual practices, and cervical human papillomavirus infection among a college population. J Clin Epidemiol. 1992 Nov;45(11):1295–1302. doi: 10.1016/0895-4356(92)90170-r. [DOI] [PubMed] [Google Scholar]
  2. Carter J. J., Hagensee M. B., Lee S. K., McKnight B., Koutsky L. A., Galloway D. A. Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology. 1994 Mar;199(2):284–291. doi: 10.1006/viro.1994.1126. [DOI] [PubMed] [Google Scholar]
  3. Carter J. J., Wipf G. C., Hagensee M. E., McKnight B., Habel L. A., Lee S. K., Kuypers J., Kiviat N., Daling J. R., Koutsky L. A. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis. 1995 Jul;172(1):11–18. doi: 10.1093/infdis/172.1.11. [DOI] [PubMed] [Google Scholar]
  4. Christensen N. D., Kirnbauer R., Schiller J. T., Ghim S. J., Schlegel R., Jenson A. B., Kreider J. W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 1994 Nov 15;205(1):329–335. doi: 10.1006/viro.1994.1649. [DOI] [PubMed] [Google Scholar]
  5. Dillner J., Kallings I., Brihmer C., Sikström B., Koskela P., Lehtinen M., Schiller J. T., Sapp M., Mårdh P. A. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis. 1996 Jun;173(6):1394–1398. doi: 10.1093/infdis/173.6.1394. [DOI] [PubMed] [Google Scholar]
  6. Dillner J., Wiklund F., Lenner P., Eklund C., Frederiksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. Int J Cancer. 1995 Jan 27;60(3):377–382. doi: 10.1002/ijc.2910600318. [DOI] [PubMed] [Google Scholar]
  7. Hagensee M. E., Olson N. H., Baker T. S., Galloway D. A. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol. 1994 Jul;68(7):4503–4505. doi: 10.1128/jvi.68.7.4503-4505.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hagensee M. E., Yaegashi N., Galloway D. A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993 Jan;67(1):315–322. doi: 10.1128/jvi.67.1.315-322.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Heim K., Christensen N. D., Hoepfl R., Wartusch B., Pinzger G., Zeimet A., Baumgartner P., Kreider J. W., Dapunt O. Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups. J Infect Dis. 1995 Aug;172(2):395–402. doi: 10.1093/infdis/172.2.395. [DOI] [PubMed] [Google Scholar]
  10. Hildesheim A., Schiffman M. H., Gravitt P. E., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P., Sherman M. E. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994 Feb;169(2):235–240. doi: 10.1093/infdis/169.2.235. [DOI] [PubMed] [Google Scholar]
  11. Hofmann K. J., Cook J. C., Joyce J. G., Brown D. R., Schultz L. D., George H. A., Rosolowsky M., Fife K. H., Jansen K. U. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology. 1995 Jun 1;209(2):506–518. doi: 10.1006/viro.1995.1283. [DOI] [PubMed] [Google Scholar]
  12. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180–12184. doi: 10.1073/pnas.89.24.12180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 1994 Apr 6;86(7):494–499. doi: 10.1093/jnci/86.7.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., Lowy D. R., Schiller J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993 Dec;67(12):6929–6936. doi: 10.1128/jvi.67.12.6929-6936.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Le Cann P., Coursaget P., Iochmann S., Touze A. Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett. 1994 Apr 15;117(3):269–274. doi: 10.1111/j.1574-6968.1994.tb06778.x. [DOI] [PubMed] [Google Scholar]
  16. Müller M., Gissmann L., Cristiano R. J., Sun X. Y., Frazer I. H., Jenson A. B., Alonso A., Zentgraf H., Zhou J. Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol. 1995 Feb;69(2):948–954. doi: 10.1128/jvi.69.2.948-954.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nonnenmacher B., Hubbert N. L., Kirnbauer R., Shah K. V., Muñoz N., Bosch F. X., de Sanjosé S., Viscidi R., Lowy D. R., Schiller J. T. Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis. 1995 Jul;172(1):19–24. doi: 10.1093/infdis/172.1.19. [DOI] [PubMed] [Google Scholar]
  18. Park D. S., Selvey L. A., Kelsall S. R., Frazer I. H. Human papillomavirus type 16 E6, E7 and L1 and type 18 E7 proteins produced by recombinant baculoviruses. J Virol Methods. 1993 Dec 31;45(3):303–318. doi: 10.1016/0166-0934(93)90115-8. [DOI] [PubMed] [Google Scholar]
  19. Roden R. B., Hubbert N. L., Kirnbauer R., Christensen N. D., Lowy D. R., Schiller J. T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996 May;70(5):3298–3301. doi: 10.1128/jvi.70.5.3298-3301.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rose R. C., Bonnez W., Da Rin C., McCance D. J., Reichman R. C. Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol. 1994 Sep;75(Pt 9):2445–2449. doi: 10.1099/0022-1317-75-9-2445. [DOI] [PubMed] [Google Scholar]
  21. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol. 1993 Apr;67(4):1936–1944. doi: 10.1128/jvi.67.4.1936-1944.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rose R. C., Bonnez W., Strike D. G., Reichman R. C. Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J Gen Virol. 1990 Nov;71(Pt 11):2725–2729. doi: 10.1099/0022-1317-71-11-2725. [DOI] [PubMed] [Google Scholar]
  23. Rose R. C., Reichman R. C., Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol. 1994 Aug;75(Pt 8):2075–2079. doi: 10.1099/0022-1317-75-8-2075. [DOI] [PubMed] [Google Scholar]
  24. Sasagawa T., Pushko P., Steers G., Gschmeissner S. E., Hajibagheri M. A., Finch J., Crawford L., Tommasino M. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology. 1995 Jan 10;206(1):126–135. doi: 10.1016/s0042-6822(95)80027-1. [DOI] [PubMed] [Google Scholar]
  25. Schiffman M. H. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol. 1994;186:55–81. doi: 10.1007/978-3-642-78487-3_4. [DOI] [PubMed] [Google Scholar]
  26. Volpers C., Schirmacher P., Streeck R. E., Sapp M. Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology. 1994 May 1;200(2):504–512. doi: 10.1006/viro.1994.1213. [DOI] [PubMed] [Google Scholar]
  27. Wideroff L., Schiffman M. H., Nonnenmacher B., Hubbert N., Kirnbauer R., Greer C. E., Lowy D., Lorincz A. T., Manos M. M., Glass A. G. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis. 1995 Dec;172(6):1425–1430. doi: 10.1093/infdis/172.6.1425. [DOI] [PubMed] [Google Scholar]
  28. Wikström A., van Doornum G. J., Quint W. G., Schiller J. T., Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol. 1995 Mar;76(Pt 3):529–539. doi: 10.1099/0022-1317-76-3-529. [DOI] [PubMed] [Google Scholar]
  29. Zhou J., Stenzel D. J., Sun X. Y., Frazer I. H. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J Gen Virol. 1993 Apr;74(Pt 4):763–768. doi: 10.1099/0022-1317-74-4-763. [DOI] [PubMed] [Google Scholar]
  30. Zhou J., Sun X. Y., Stenzel D. J., Frazer I. H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991 Nov;185(1):251–257. doi: 10.1016/0042-6822(91)90772-4. [DOI] [PubMed] [Google Scholar]
  31. de Villiers E. M., Wagner D., Schneider A., Wesch H., Miklaw H., Wahrendorf J., Papendick U., zur Hausen H. Human papillomavirus infections in women with and without abnormal cervical cytology. Lancet. 1987 Sep 26;2(8561):703–706. doi: 10.1016/s0140-6736(87)91072-5. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES